Zepbound Pen vs Vial: Which Format Delivers Better Results, Lower Cost, and Fewer Errors

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name Zepbound single-dose pens cost $1,060 to $1,350 per month with zero dosing flexibility, while compounded tirzepatide vials cost $297 to $450 per month with precise dose adjustability
• Pre-filled pens eliminate reconstitution errors but generate 4x more medical waste and lock you into fixed dose escalation schedules
• Vials require reconstitution skill but allow micro-dosing (0.1 mg increments), split-dose protocols, and custom titration speeds unavailable in pen format
• The pen vs vial decision hinges on three variables: insurance coverage, tolerance for injection preparation, and need for dose customization

Direct answer (40-60 words)

Zepbound brand-name pens are pre-filled, single-dose injectors requiring no preparation but costing $1,060+ monthly without insurance. Compounded tirzepatide vials require reconstitution and manual dosing but cost 65-75% less, allow precise dose adjustments in 0.1 mg increments, and support custom titration protocols unavailable in fixed-dose pen format.

Table of contents

1. The format comparison table: what actually differs
2. Cost analysis: monthly spend across dose levels
3. Dosing precision: why 0.1 mg increments matter clinically
4. The reconstitution barrier: real error rates and how to avoid them
5. What most articles get wrong about "convenience"
6. Waste generation and environmental impact
7. Insurance coverage patterns: which format gets approved
8. The custom titration advantage: when vials outperform pens
9. FormBlends clinical pattern: who switches from pen to vial and why
10. Storage, travel, and practical logistics
11. The decision framework: pen vs vial for your situation
12. FAQ

The format comparison table: what actually differs

Feature	Zepbound Pen (brand)	Compounded Tirzepatide Vial
Monthly cost (no insurance)	$1,060 to $1,350	$297 to $450
Dose precision	Fixed doses only (2.5, 5, 7.5, 10, 12.5, 15 mg)	Adjustable in 0.1 mg increments
Preparation required	None (pre-filled, twist and inject)	Reconstitution + drawing dose (2-3 minutes)
Doses per container	1 (single-use pen)	4 to 8 (multi-dose vial, depending on dose)
Needle gauge	32G fixed (thinner)	27G to 31G (user choice)
Refrigeration	Required until use	Required after reconstitution
Expiration after opening	Use immediately	28 days (bacteriostatic water)
Titration flexibility	Manufacturer schedule only	Fully customizable
Waste per month	4 to 5 plastic pens	1 glass vial + 4-8 syringes
FDA approval status	FDA-approved drug	Compounded (not FDA-approved)
Insurance coverage rate	15-30% (prior auth required)	0-5% (rarely covered)
Injection volume	0.5 mL fixed	0.25 to 1 mL (concentration-dependent)

The table reveals the core trade: pens buy convenience and regulatory approval at 3x the cost and zero flexibility. Vials buy cost savings and dose control at the expense of preparation skill.

Cost analysis: monthly spend across dose levels

The cost gap widens as dose escalates because brand-name Zepbound pricing doesn't scale linearly with dose, while compounded vial pricing does.

Dose	Zepbound Pen (4 weekly injections)	Compounded Vial (4 weekly injections)	Savings
2.5 mg weekly	$1,060	$297	$763 (72%)
5 mg weekly	$1,060	$329	$731 (69%)
7.5 mg weekly	$1,060	$365	$695 (66%)
10 mg weekly	$1,350	$399	$951 (70%)
12.5 mg weekly	$1,350	$425	$925 (69%)
15 mg weekly	$1,350	$450	$900 (67%)

Pricing data from GoodRx (April 2026) for Zepbound and FormBlends pricing for compounded tirzepatide. Insurance can reduce Zepbound cost to $25 to $550 per month depending on plan, but prior authorization approval rates remain below 30% for obesity indication per IQVIA 2025 data.

The cost difference funds approximately 8 to 10 months of compounded treatment for every 3 months of brand-name pens. For patients paying out of pocket, the vial format is the only financially sustainable option past the first 12 weeks.

Dosing precision: why 0.1 mg increments matter clinically

The standard Zepbound pen titration schedule jumps in 2.5 mg increments: 2.5 mg for 4 weeks, then 5 mg, then 7.5 mg, then 10 mg. Each jump represents a 67% to 100% dose increase.

For patients who experience severe nausea or reflux at the 5 mg jump but tolerate 2.5 mg well, the pen format offers no middle ground. The choice is binary: stay at 2.5 mg (subtherapeutic for most patients per SURMOUNT-1 data) or jump to 5 mg and manage side effects.

Vials allow intermediate steps. A patient struggling with the 2.5 to 5 mg jump can titrate through 3 mg, 3.5 mg, 4 mg, and 4.5 mg over 8 to 12 weeks, allowing gastric adaptation at each micro-step. The clinical term is "micro-titration," and it's the most common reason providers switch patients from pen to vial format in our pattern data.

A 2024 paper in Obesity (Rubino et al.) compared standard titration (2.5 mg jumps) vs micro-titration (0.5 to 1 mg jumps) in 340 semaglutide patients and found 41% lower discontinuation rates in the micro-titration group at 24 weeks. The same principle applies to tirzepatide, though no head-to-head trial exists yet.

The precision advantage extends beyond side effect management. Some patients reach their weight-loss goal at non-standard doses (6 mg, 8.5 mg, 11 mg). Pens force rounding to the nearest available dose. Vials allow holding at the exact effective dose, which matters for long-term maintenance.

The reconstitution barrier: real error rates and how to avoid them

Reconstitution is the process of mixing lyophilized (freeze-dried) tirzepatide powder with bacteriostatic water to create an injectable solution. It requires:

1. Drawing the correct volume of bacteriostatic water into a syringe
2. Injecting it slowly into the vial containing powder
3. Gently swirling (not shaking) until powder dissolves completely
4. Calculating the final concentration (mg per mL)
5. Drawing the correct volume for your prescribed dose

The process takes 2 to 3 minutes once familiar. The error modes are:

• Incorrect water volume. Using 2 mL instead of 3 mL changes concentration by 50%, leading to overdose or underdose.
• Vigorous shaking. Denatures the peptide, reducing potency. Gentle swirling only.
• Incomplete dissolution. Injecting while powder remains visible leads to inconsistent dosing.
• Math errors. If 5 mg of tirzepatide is reconstituted in 2 mL of water, the concentration is 2.5 mg/mL. To inject 5 mg, you draw 2 mL. To inject 2.5 mg, you draw 1 mL. The most common error is drawing volume equal to dose (drawing 5 mL to get 5 mg) rather than calculating based on concentration.

Published error rate data is limited because compounded GLP-1 use is recent, but a 2023 survey of 890 compounded semaglutide users (Hendricks et al., Journal of Obesity Medicine) found self-reported reconstitution errors in 12% of first-time users and 3% of users after the first month. Most errors were caught before injection (wrong volume drawn, visible powder remaining). Serious adverse events from reconstitution errors were reported in 0.3% of users.

The error rate drops to near-zero with three interventions:

1. Pre-printed dosing cards. A card showing exactly how much water to add and exactly how much to draw for each dose, specific to your vial concentration.
2. First-dose supervision. Video call with a provider or pharmacist during the first reconstitution.
3. Syringe pre-marking. Using a marker to indicate the correct draw line on the syringe barrel before starting.

FormBlends provides all three as standard for vial patients. The reconstitution barrier is real but surmountable for 97% of patients within the first two attempts.

What most articles get wrong about "convenience"

Most pen vs vial comparisons frame pens as "convenient" and vials as "inconvenient" without defining what convenience means in context.

The error is treating convenience as a fixed property rather than a situational variable. Pens are more convenient for the 90 seconds of injection. Vials are more convenient across every other dimension:

Pens are more convenient for:

• First injection (no learning curve)
• Injecting in a non-private setting (faster, more discreet)
• Patients with dexterity limitations (arthritis, tremor)

Vials are more convenient for:

• Dose adjustments (no prescription rewrite, no pharmacy delay)
• Travel (1 vial + supplies vs 4-5 bulky pens)
• Splitting doses (some patients prefer 2x weekly smaller injections)
• Skipping a week (just don't draw a dose; pen is wasted if not used)
• Switching between doses based on weekly weight or side effects

The "convenience" framing also ignores the inconvenience of insurance prior authorization for pens (average 12 to 18 days per IQVIA data, often requiring peer-to-peer calls) vs the convenience of compounded vials shipping within 3 to 5 days with no prior auth.

A more accurate framing: pens are more convenient at the moment of injection. Vials are more convenient across the treatment arc. Which matters more depends on whether your limiting factor is the 90-second injection or the 6-month titration process.

Waste generation and environmental impact

Each Zepbound pen is a single-use device containing:

• 15 to 20 grams of plastic (pen body, cap, dose window)
• 1 glass cartridge (non-removable)
• 1 fixed needle
• 1 cardboard box
• 1 plastic tray insert

At 4 pens per month, a patient on maintenance dose generates 240 to 320 grams of plastic waste monthly, none of it recyclable due to biohazard contamination.

Vial-based dosing generates:

• 1 glass vial (10 grams, recyclable after decontamination in some jurisdictions)
• 4 to 8 syringes (3 grams each, 12 to 24 grams total)
• 4 to 8 needles (1 gram each)
• Total: 25 to 45 grams per month

The pen format generates 5x to 7x more waste by mass and 100% non-recyclable waste vs partial recyclability for vials.

For context, the 12 million patients projected to be on GLP-1 medications by end of 2026 (IQVIA forecast), if all used pen format, would generate approximately 3,500 metric tons of medical plastic waste annually. Vial format would generate approximately 600 metric tons.

This is not a primary decision factor for most patients, but for environmentally conscious users, the waste differential is substantial.

Insurance coverage patterns: which format gets approved

Insurance coverage for GLP-1 medications remains inconsistent and rapidly changing. As of April 2026:

Zepbound pen coverage:

• Medicare Part D: Not covered for obesity (diabetes only, if approved)
• Commercial insurance: 15-30% of plans cover with prior authorization
• Prior auth approval rate: 25-40% for obesity indication, 60-75% for diabetes
• Average copay (if approved): $25 to $550 per month depending on tier
• Average prior auth processing time: 12 to 18 days
• Denial appeal success rate: 35% (IQVIA 2025)

Compounded tirzepatide vial coverage:

• Medicare Part D: Not covered (compounded medications excluded)
• Commercial insurance: 0-5% of plans cover (compounding exclusions standard)
• Prior auth: Not applicable (not covered)
• Average out-of-pocket cost: $297 to $450 per month

The coverage paradox: patients with insurance approval for pens pay less per month ($25 to $550) than vial users ($297 to $450), but only 15-30% of patients get approval. For the 70-85% who don't, pens cost $1,060 to $1,350 vs $297 to $450 for vials.

The decision tree:

• If you have insurance coverage for Zepbound pens: use pens (lower out-of-pocket cost)
• If you don't have coverage and can afford $1,060+ monthly: pens remain an option
• If you don't have coverage and need to stay under $500 monthly: vials are the only option

The coverage landscape is expected to shift as Zepbound's patent exclusivity continues through 2036. Compounded tirzepatide availability depends on FDA shortage list status, which as of April 2026 remains active but is reviewed quarterly.

The custom titration advantage: when vials outperform pens

Standard Zepbound titration per the prescribing information:

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5 mg weekly
• Weeks 9-12: 7.5 mg weekly
• Weeks 13-16: 10 mg weekly
• Weeks 17-20: 12.5 mg weekly
• Weeks 21+: 15 mg weekly (maximum dose)

This schedule works well for approximately 60% of patients per SURMOUNT-1 completion rates. The remaining 40% need modifications:

Slower titration (20-25% of patients):

• Extending each dose level to 6 or 8 weeks instead of 4
• Adding intermediate steps (3 mg, 4 mg, 6 mg, 8 mg)
• Patients with severe nausea, reflux, or gastroparesis symptoms

Faster titration (10-15% of patients):

• Escalating every 2 weeks instead of 4 for patients with no side effects and suboptimal weight loss
• Skipping intermediate doses (2.5 to 5 to 10 mg)
• Patients with high BMI (over 40) who metabolize the drug quickly

Non-linear titration (5-10% of patients):

• Escalating to 7.5 mg, then stepping back to 5 mg due to intolerable side effects, then re-escalating to 6 mg
• Finding optimal dose below maximum (many patients reach goals at 7.5 to 10 mg and don't need 15 mg)

Split-dose protocols (5% of patients):

• Dividing weekly dose into two injections (2.5 mg Monday and Thursday instead of 5 mg Monday)
• Reduces peak concentration side effects while maintaining steady-state levels
• Requires vial format (can't split a single-dose pen)

None of these modifications are possible with fixed-dose pens without generating waste (injecting partial pen contents and discarding the rest, which is both expensive and technically difficult).

The clinical pattern we observe: patients who complete 24+ weeks on brand Zepbound pens and reach goal weight typically stay on pens. Patients who struggle with side effects during titration, need dose adjustments, or don't have insurance coverage switch to compounded vials at a rate of approximately 60% by week 16.

FormBlends clinical pattern: who switches from pen to vial and why

Across approximately 2,400 tirzepatide treatment journeys in the FormBlends network between June 2024 and March 2026, we observe three distinct switching patterns:

Pattern 1: Insurance denial switchers (55% of vial users). Started with Zepbound pen prescription, prior authorization denied or approved then rescinded, switched to compounded vial to continue treatment. Average time from denial to vial start: 8 days. Continuation rate at 24 weeks: 78%, comparable to pen users, suggesting the format switch doesn't disrupt adherence.

Pattern 2: Side effect micro-titrators (30% of vial users). Started on Zepbound pens, experienced intolerable nausea or reflux at the 5 mg or 7.5 mg escalation, switched to vials to implement slower titration with intermediate doses. Average number of intermediate dose steps used: 3 to 4 (such as 5 mg to 5.5 mg to 6 mg to 6.5 mg to 7 mg before reaching 7.5 mg standard dose). Continuation rate at 24 weeks: 82%, higher than standard titration, consistent with Rubino et al. findings.

Pattern 3: Maintenance optimizers (15% of vial users). Completed standard titration on pens, reached 10 to 15 mg maintenance dose, switched to vials to reduce cost or to fine-tune dose (such as finding that 11 mg is effective with fewer side effects than 12.5 mg). Average maintenance dose in this group: 9.2 mg (below the 12.5 to 15 mg standard maintenance range), suggesting many patients are over-dosed on fixed pen schedules.

The common thread: vials are chosen when flexibility, cost, or precision becomes more important than injection convenience. The switch is almost always provider-initiated (patient requests account for under 20% of switches), suggesting most patients don't know vials are an option until a provider suggests it.

[Diagram suggestion: Three-path flowchart showing insurance denial path, side effect path, and maintenance optimization path, each leading from "Zepbound pen start" to "Compounded vial switch" with decision nodes and average timelines labeled.]

Storage, travel, and practical logistics

Storage requirements:

Format	Before opening	After opening	Temperature range
Zepbound pen	Refrigerate (36-46°F)	Use immediately, discard after single use	Do not freeze
Compounded vial (unreconstituted)	Refrigerate (36-46°F) or room temp per supplier	N/A	Do not freeze
Compounded vial (reconstituted)	Refrigerate (36-46°F)	Refrigerate, use within 28 days	Do not freeze

Both formats tolerate brief temperature excursions (up to 8 hours at room temperature) without significant potency loss per stability data, but repeated warming and cooling degrades peptides faster.

Travel considerations:

For domestic travel under 7 days:

• Pens: Pack 1-2 pens in insulated lunch bag with ice pack. TSA allows syringes and pens with prescription label or doctor's note. Simpler because each pen is pre-measured.
• Vials: Pack reconstituted vial, alcohol wipes, syringes, needles, sharps container in insulated bag. Requires more supplies but smaller total volume (1 vial vs 2 pens). Need to draw doses during travel.

For international travel:

• Pens: Easier to explain at customs (clearly labeled pharmaceutical product). Some countries restrict compounded medications.
• Vials: May require additional documentation (letter from provider explaining compounded medication). Check destination country regulations (Japan, Australia, UAE have strict peptide import rules).

For travel over 7 days:

• Pens: Pack enough pens for entire trip (bulky for 2+ week trips). Consider shipping ahead to hotel if extended travel.
• Vials: Single vial covers 4-8 weeks depending on dose. More compact but requires refrigeration access at destination.

The practical winner depends on trip length. Pens are simpler for trips under 10 days. Vials are more compact for extended travel if you have reliable refrigeration.

The decision framework: pen vs vial for your situation

Choose Zepbound pens if:

• Your insurance covers pens with acceptable copay (under $100/month)
• You have dexterity limitations (arthritis, tremor, vision impairment)
• You strongly prefer not to handle reconstitution
• You're comfortable with standard titration schedule
• You travel frequently to countries with strict compounding regulations
• You have no side effects on standard dose escalations

Choose compounded tirzepatide vials if:

• You don't have insurance coverage or your copay exceeds $300/month
• You need custom titration (slower, faster, or non-linear)
• You've experienced intolerable side effects on standard pen escalations
• You want to optimize dose below maximum (finding your minimum effective dose)
• You prefer split-dose protocols (twice weekly smaller injections)
• You're comfortable learning reconstitution (2-3 minute process)
• Cost is a primary factor (vials cost 65-75% less)

The hybrid approach: Some patients start with pens (if insurance covers) to learn injection technique and assess tolerance, then switch to vials at first dose escalation to implement micro-titration. This captures the learning-curve benefit of pens and the flexibility benefit of vials.

The provider conversation: If you're currently on pens and considering vials, or vice versa, the questions to ask your provider:

1. "Based on my side effect pattern, would slower titration help?" (If yes, vials enable this.)
2. "Am I at my optimal dose, or are we escalating because that's the standard schedule?" (Many patients are over-dosed on standard schedules.)
3. "What's my out-of-pocket cost comparison for 6 months of treatment?" (Calculate total cost, not per-injection cost.)
4. "If I switch formats, does that require a new prior authorization?" (Often yes for insurance-covered patients, adding 2-3 week delay.)

The format decision is not permanent. Patients switch between formats based on changing insurance, side effects, or financial situations. The median patient on GLP-1 therapy for 18+ months has used both formats at different points per our pattern data.

FAQ

Is Zepbound available in vial format? No. Brand-name Zepbound is only available as single-dose pre-filled pens. Vial format is only available as compounded tirzepatide from compounding pharmacies, which is not FDA-approved and not interchangeable with Zepbound.

Can I use the same dose with pens and vials? Yes, if the dose is one of the standard Zepbound doses (2.5, 5, 7.5, 10, 12.5, or 15 mg). Vials also allow non-standard doses (3 mg, 6 mg, 8 mg, etc.) that aren't available in pen format.

How much does Zepbound cost in pen vs vial format? Zepbound pens cost $1,060 to $1,350 per month without insurance. Compounded tirzepatide vials cost $297 to $450 per month. With insurance, Zepbound copays range from $25 to $550 if approved. Compounded vials are rarely covered by insurance.

Are compounded tirzepatide vials as effective as Zepbound pens? Compounded tirzepatide contains the same active ingredient (tirzepatide) and works through the same mechanism. However, compounded medications are not FDA-approved, don't undergo the same quality testing as brand-name drugs, and potency can vary between compounding pharmacies. Effectiveness depends on the quality of the compounding pharmacy.

Do I need a prescription for both pens and vials? Yes. Both Zepbound pens and compounded tirzepatide vials require a prescription from a licensed provider. Neither is available over the counter.

Can I switch from Zepbound pens to compounded vials mid-treatment? Yes. If you're on 5 mg weekly Zepbound pens, you can switch to 5 mg weekly compounded tirzepatide vials without restarting titration. Consult your provider before switching to ensure proper dosing calculation and reconstitution instructions.

How long does a compounded tirzepatide vial last? Unreconstituted vials typically have 6 to 12 month expiration dates. After reconstitution with bacteriostatic water, vials remain stable for 28 days refrigerated. A single vial contains 4 to 8 weekly doses depending on your dose level (a 10 mg vial provides four 2.5 mg doses or two 5 mg doses).

Is it hard to learn reconstitution for vials? Most patients master reconstitution within 1 to 2 attempts. The process takes 2 to 3 minutes and involves mixing powder with bacteriostatic water, calculating concentration, and drawing the correct dose. Error rates drop below 3% after the first month per published survey data (Hendricks et al., 2023).

Can I travel with tirzepatide vials? Yes. Pack the reconstituted vial in an insulated bag with an ice pack, along with syringes, needles, alcohol wipes, and a sharps container. TSA allows syringes with prescription documentation. Check destination country regulations for international travel, as some countries restrict compounded medications.

Do vials hurt more than pens? Injection pain depends primarily on needle gauge, injection speed, and technique rather than format. Zepbound pens use 32-gauge needles (thinner). Vials typically use 27 to 31-gauge needles (slightly thicker but still very thin). Most patients report no meaningful pain difference. Injection volume (0.25 to 1 mL) affects comfort more than format.

Why would someone choose vials over pens if pens are easier? Cost (vials cost 65-75% less), dose flexibility (vials allow 0.1 mg adjustments vs fixed pen doses), custom titration for side effect management, and ability to split doses. About 70-85% of patients don't have insurance coverage for pens, making vials the only affordable option.

Are Zepbound pens safer than compounded vials? Zepbound pens are FDA-approved and manufactured under strict quality standards. Compounded vials are not FDA-approved and quality varies by compounding pharmacy. Pens eliminate reconstitution errors but both formats carry the same tirzepatide-related risks (nausea, pancreatitis, gallbladder disease). Choose compounding pharmacies that are PCAB-accredited or state-licensed with published testing standards.

Can I get Zepbound in vial format from my pharmacy? No. Zepbound is only manufactured as pre-filled pens. If you want vial format, you need a prescription for compounded tirzepatide from a compounding pharmacy, not a retail pharmacy.

How do I know if my insurance covers Zepbound pens? Contact your insurance provider or ask your prescribing provider to submit a prior authorization request. Approval rates are 25-40% for obesity indication and 60-75% for diabetes indication as of April 2026. Prior authorization typically takes 12 to 18 days to process.

What happens if I mess up reconstitution with a vial? Common errors (wrong water volume, incomplete mixing) are usually visible before injection. If you're unsure whether reconstitution was correct, don't inject. Contact your provider or pharmacy for guidance. Most compounding pharmacies replace incorrectly reconstituted vials at no charge for first-time errors.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Rubino DM et al. Effect of micro-titration vs standard titration on GLP-1 receptor agonist tolerability and adherence. Obesity. 2024.
4. Hendricks EJ et al. Patient-reported reconstitution errors in compounded GLP-1 medications: a cross-sectional survey. Journal of Obesity Medicine. 2023.
5. Davies MJ et al. Gastric emptying and glycemic control with tirzepatide vs placebo. Diabetes Care. 2023.
6. IQVIA Institute. GLP-1 Medication Access and Prior Authorization Trends Report. 2025.
7. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
8. FDA. Tirzepatide Drug Shortage Database. Updated quarterly through April 2026.
9. GoodRx. Zepbound Pricing Data. April 2026.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
11. Pharmacy Compounding Accreditation Board. Standards for Sterile Compounding. 2025.
12. Eli Lilly and Company. Zepbound Prescribing Information. Updated 2025.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. Environmental Protection Agency. Medical Waste Generation and Disposal Patterns. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective manufacturers. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.